• +1-646-491-9876
    • +91-20-67278686

    Search

    Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017

    Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017

    • Report Code ID: RW0001689462
    • Category Healthcare
    • No. of Pages 90
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

    Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 3, 2, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
    - The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Acute Respiratory Distress Syndrome - Overview
    Acute Respiratory Distress Syndrome - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Acute Respiratory Distress Syndrome - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
    Altor BioScience Corp
    Athersys Inc
    Commence Bio Inc
    Faron Pharmaceuticals Oy
    GlaxoSmithKline Plc
    Global Blood Therapeutics Inc
    Hydra Biosciences Inc
    Implicit Bioscience Ltd
    Phylogica Ltd
    Savara Inc
    Silence Therapeutics Plc
    Acute Respiratory Distress Syndrome - Drug Profiles
    ALT-836 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIO-10901 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIO-11006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CMB-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GBT-440 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2586881 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2862277 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HC-067047 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IC-14 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon beta-1a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LT-1001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    molgramostim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-05285401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PYC-35 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PYC-36 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PYC-38 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PYC-98 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-1229 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAN-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Acute Respiratory Distress Syndrome - Dormant Projects
    Acute Respiratory Distress Syndrome - Discontinued Products
    Acute Respiratory Distress Syndrome - Product Development Milestones
    Featured News & Press Releases
    Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation
    Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial
    Sep 03, 2016: Queen’s University Developing New Drug against Leading Causes of Death in the UK - Sepsis and Ards
    May 25, 2016: First patient dosed in Savaras pivotal trial for PAP
    Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation
    Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
    Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
    Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP
    Aug 09, 2015: Serendex to initiate first phase II clinical trial
    Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November
    May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
    May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases
    May 10, 2015: Positive topline data from Serendex phase I clinical trial
    Feb 27, 2015: Serendex submits phase I application
    Feb 13, 2015: Serendex partners up with leading German lung center
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corp, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics Inc, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Phylogica Ltd, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H1 2017
    Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H1 2017
    Acute Respiratory Distress Syndrome - Dormant Projects, H1 2017
    Acute Respiratory Distress Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Acute Respiratory Distress Syndrome - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Altor BioScience Corp
    Athersys Inc
    Commence Bio Inc
    Faron Pharmaceuticals Oy
    GlaxoSmithKline Plc
    Global Blood Therapeutics Inc
    Hydra Biosciences Inc
    Implicit Bioscience Ltd
    Phylogica Ltd
    Savara Inc
    Silence Therapeutics Plc

    Request for Sample

    Report Url http://www.reportsweb.com//acute-respiratory-distress-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//acute-respiratory-distress-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//acute-respiratory-distress-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments